Humana Earnings: Balanced Membership and Profit Growth Contribute to Higher 2023 Outlook

""
Securities In This Article
Humana Inc
(HUM)

Narrow-moat Humana HUM turned in a strong start to the year and mildly increased its guidance for 2023. We have tinkered with our near-term assumptions a bit, but we are maintaining our $550 fair value estimate.

In the quarter, Humana’s strong annual election period in Medicare Advantage was on display, outpacing most of its peers. Part of this outperformance may relate to Humana’s strong MA Star Ratings scores, which were announced in October, and were much better than the other managed-care organizations that we cover, holding relatively steady at 96% of members expected to be in 4-star plans or better. This is versus a similar 97% last year while most other providers’ MA scoring percentages declined substantially. With these strong scores and other benefits likely attracting seniors when choosing their 2023 plans, Humana delivered 14% individual MA membership growth year over year relative to a weak 2022 period when Humana was more conservative with pricing, resulting in lower membership growth but stellar profit growth last year. In 2023, Humana aims to better balance MA membership and profit growth, and it appears to be doing well on that front, turning in 20% adjusted EPS growth in the first quarter.

On that strength, Humana slightly increased its 2023 outlook. Management now expects at least $28.25 of adjusted EPS (up from $28 previously) and representing growth of 12% year over year, or near the weak end of its long-term earnings growth target of 11% to 15%. Management also maintained its 2025 earnings target of $37 per share, which represents about 14% growth compounded annually from 2022 to 2025, or near the top of its long-term target. We are raising our 2023 assumptions a bit on the first quarter’s strong trends, and our longer-term estimates remain in line with management’s guidance. However, our fair value estimate has not changed materially, and shares appear about fairly valued, despite some of the industrywide MA headwinds expected to arise in 2024.

The author or authors do not own shares in any securities mentioned in this article. Find out about Morningstar’s editorial policies.

More in Stocks

About the Author

Julie Utterback, CFA

Senior Equity Analyst
More from Author

Julie Utterback, CFA, is a senior equity analyst, AM Healthcare, for Morningstar*. She focuses on medical technology and service companies. She covers managed care organizations including UnitedHealth, service providers like HCA, medical suppliers such as Baxter, and life sciences companies like Danaher. She is also the chairperson of the equity research team’s capital allocation methodology.

Before joining Morningstar in 2005, Utterback was an equity analyst at State Farm Insurance for several years. Utterback joined Morningstar in 2005 as an equity analyst in the healthcare industry, and initially she primarily covered medical technology companies, including orthopedic device, medical equipment, and cardiac device firms. In 2010, she joined Morningstar's credit research team, initiating coverage of the entire healthcare industry and generally helping the organization expand and maintain its credit coverage across many industries. She held that senior credit analyst role until April 2019, when she returned to the equity team to cover medical technology and service companies.

Utterback holds a bachelor's degree in finance from the University of Illinois Urbana-Champaign’s Gies College of Business. She also holds the Chartered Financial Analyst® designation.

* Morningstar Research Services LLC (“Morningstar”) is a wholly owned subsidiary of Morningstar, Inc

Sponsor Center